<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413789</url>
  </required_header>
  <id_info>
    <org_study_id>2011/350</org_study_id>
    <nct_id>NCT01413789</nct_id>
  </id_info>
  <brief_title>Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels and One Gel Cream</brief_title>
  <official_title>Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels: BAP Scar Gel, Dermatix, Kelocote and One Gel- Cream: Alhydran</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis: Is Alhydran gel-cream as efficient as silicone gel for skin occlusion and
      hydration?

      For this study 16 volunteers and ten patients with healed full thickness burns will be
      included.

      After a short period of acclimatization four test areas will be determined. For healthy
      volunteers the standard zones are located on the inner forearm, two on each forearm.

      For patients with healed burns the 4 test zones are located on either the healed donor site
      or the healed skin grafted area.

      In each test zone baseline measurements will be taken before application of the
      products.After application of the three silicone gels and the hydrating gel cream the trans
      epidermal water loss (TEWL) and the moisture content of the stratum corneum will be measured
      by using the TEWAmeter®TM300 and the Corneometer® CM825 (Courage &amp; Khazaka).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occlusive and hydrating capacity of the products.</measure>
    <time_frame>1 hour after application</time_frame>
    <description>Measurements will be done by using the TEWAmeter® for measurement of the Trans Epidermal Waterloss and the Corneometer® 825CM for measurement of the moisture content of the stratum corneum (Courage &amp; Khazaka). For this study no risk factors are determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occlusive and hydrating capacity of the products.</measure>
    <time_frame>2 hours after application</time_frame>
    <description>Measurements will be done by using the TEWAmeter® for measurement of the Trans Epidermal Waterloss and the Corneometer® 825CM for measurement of the moisture content of the stratum corneum (Courage &amp; Khazaka). For this study no risk factors are determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occlusive and hydrating capacity of the products.</measure>
    <time_frame>3 hours after application</time_frame>
    <description>Measurements will be done by using the TEWAmeter® for measurement of the Trans Epidermal Waterloss and the Corneometer® 825CM for measurement of the moisture content of the stratum corneum (Courage &amp; Khazaka). For this study no risk factors are determined.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Scar Tissue or Healthy Skin</condition>
  <arm_group>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with healed full thickness burns and healthy volunteers will be included in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dermatix</intervention_name>
    <description>1 application of Dermatix</description>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kelocote</intervention_name>
    <description>1 application of Kelocote</description>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAP scar gel</intervention_name>
    <description>1 application of BAP scar gel</description>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alhydran</intervention_name>
    <description>1 application of Alhydran</description>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bap Scar Care T</intervention_name>
    <description>1 application of BAP Scar Care T</description>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bap Scar Care S</intervention_name>
    <description>1 Application of Bap Scar Care S</description>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepiform</intervention_name>
    <description>1 application of Mepiform</description>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scar Ban Elastic</intervention_name>
    <description>1 application of Scar Ban Elastic</description>
    <arm_group_label>Patients and healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers or patients with healed full thickness burns and donor sites

          -  not pregnant

          -  age&gt;18 years

          -  male or female

          -  written authorisation of the patient or volunteer is required.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Monstrey, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

